Zdrowie i gospodarka · 07/02/2014

FDA to Host Public Meeting on Patient-Focused Drug Development for Pulmonary Arterial Hypertension

The Food and Drug Administration (FDA) is hosting a public meeting to gather patients' perspectives on pulmonary arterial hypertension and its treatment options, as part of its performance commitments under the Prescription Drug User Fee Act (PDUFA V). The meeting aims to inform the development of new treatments for this condition.